
Chinese General Practice ›› 2023, Vol. 26 ›› Issue (34): 4336-4342.DOI: 10.12114/j.issn.1007-9572.2022.0896
Special Issue: 中医最新文章合辑
• Evidence-based Medicine • Previous Articles Next Articles
Received:2022-10-17
Revised:2023-06-02
Published:2023-12-05
Online:2023-06-30
Contact:
HAN Jing
通讯作者:
韩晶
作者简介:基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0896
| 第一作者 | 发表时间(年) | 试验组治疗方案 | 对照组治疗方案 | 样本量(试验组/对照组,例) | 治愈率〔例(%)〕 | 有效率〔例(%)〕 | 治疗后VAS( | 改良Jadad量表评分(分) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 试验组 | 对照组 | 试验组 | 对照组 | 试验组 | 对照组 | ||||||
| 陈硕康[ | 2017 | 通元针法每周3次,共12周 | 氟桂利嗪(10 mg)每晚1次,共12周 | 38/36 | 47.37(18/38) | 38.89(14/36) | 97.37(37/38) | 94.44(34/36) | 4.55±0.69 | 5.09±0.97 | 7 |
| 关淑婷[ | 2019 | 治神六穴每周5次,共4周 | 氟桂利嗪(5 mg)每晚1次,每周5次,共4周 | 60/59 | 5.00(3/60) | 1.69(1/59) | 96.67(58/60) | 81.36(48/59) | 2.62±0.89 | 3.39±0.78 | 5 |
| 戴睛[ | 2017 | 骨边刺每周3次,共4周 | 尼莫地平(40 mg)每日3次,共4周 | 35/45 | 17.14(6/35) | 8.89(4/45) | 94.29(33/35) | 75.56(34/45) | 3.14±2.00 | 4.42±2.27 | 1 |
| 郭伟[ | 2011 | 常规针刺每日1次,共20 d | 阿司匹林(0.3 g)每日3次,共20 d | 35/33 | 80.00(28/35) | 0(0/33) | 94.29(33/35) | 42.42(14/33) | 0.30±0.83 | 2.74±1.68 | 2 |
| 刘云霞[ | 2020 | 常规针刺每日1次,共21 d | 氟桂利嗪(5 mg)每日2次,共30 d | 59/59 | 59.32(35/59) | 32.20(19/59) | 96.61(57/59) | 83.05(49/59) | 3.10±1.58 | 4.60±1.87 | 1 |
| 舒伟[ | 2017 | 常规针刺每日1次,共4周 | 氟桂利嗪(10 mg)每晚1次,共4周 | 58/57 | 41.38(24/58) | 28.07(16/57) | 98.28(57/58) | 89.47(51/57) | 3.41±1.26 | 3.38±1.02 | 2 |
| 苏慧媛[ | 2016 | 常规针刺每日1次,共4周 | 氟桂利嗪(5 mg)每晚1次,共4周 | 35/32 | 28.57(10/35) | 9.38(3/32) | 91.43(32/35) | 78.13(25/32) | 1.54±0.74 | 2.86±0.92 | 2 |
| 崔晶[ | 2016 | 常规针刺每周2次,共6周 | 对乙酰氨基酚(1 g)按需服用,共6周 | 32/33 | 25.00(8/32) | 6.06(2/33) | 87.50(28/32) | 69.70(23/33) | 2.73±2.22 | 3.11±1.72 | 7 |
| 张瑞秋[ | 2021 | 常规针刺每日1次,共24 d | 氟桂利嗪(5 mg)每晚1次,共24 d | 43/42 | 18.60(8/43) | 4.76(2/42) | 90.70(39/43) | 73.81(31/42) | 3.42±1.14 | 5.48±1.40 | 3 |
| 陈慧[ | 2019 | 胆经每日1次,共20 d | 氟桂利嗪(5 mg)每晚1次,共20 d | 50/48 | 64.00(32/50) | 22.92(11/48) | 90.00(45/50) | 72.92(35/48) | 0.85±0.28 | 1.13±1.09 | 3 |
| 于明[ | 2017 | 胆经、三焦经每周3次,共12周 | 氟桂利嗪(5 mg)每晚1次,每周5 d,共12周 | 41/43 | 48.78(20/41) | 41.86(18/43) | 95.12(39/41) | 88.37(38/43) | 2.07±0.31 | 2.40±0.47 | 1 |
| 卢金荣[ | 2014 | 头部腧穴每日1次,共10 d | 尼莫地平(40 mg)每日3次,共10 d | 48/48 | 41.67(20/48) | 10.42(5/48) | 91.67(44/48) | 62.50(30/48) | 2.17±1.88 | 3.76±2.42 | 1 |
| 杨佳[ | 2018 | 头部腧穴每周3次,共4周 | 氟桂利嗪(用法用量不详) | 20/19 | 75.00(15/20) | 52.63(10/19) | 95.00(19/20) | 78.95(15/19) | 3.40±1.39 | 4.58±1.17 | 6 |
| 景允南[ | 2021 | 透刺法隔日1次,共28 d | 氟桂利嗪(5 mg)每晚1次,共4周 | 31/33 | 58.06(18/31) | 33.33(11/33) | 96.77(30/31) | 87.88(29/33) | 2.71±1.55 | 3.94±1.46 | 7 |
| 刘波[ | 2021 | 透刺法每日1次,共28 d | 氟桂利嗪(5 mg)每晚1次,共4周 | 40/40 | 15.00(6/40) | 5.00(2/40) | 97.50(39/40) | 85.00(34/40) | 2.57±1.05 | 3.54±1.19 | 1 |
| 杨雄庆[ | 2013 | 透刺法隔日1次,共40 d | 氟桂利嗪(5 mg)每日1次,共30 d | 30/28 | 56.67(17/30) | 28.57(8/28) | 96.67(29/30) | 78.57(22/28) | 2.40±1.04 | 4.12±1.10 | 2 |
| 杨旭光[ | 2006 | 四关穴每周3次,共4周 | 氟桂利嗪(5 mg)每日2次,共4周 | 35/33 | 22.86(8/35) | 15.15(5/33) | 91.43(32/35) | 72.73(24/33) | 1.31±0.57 | 1.67±0.85 | 5 |
Table 1 The basic characteristics of included studies
| 第一作者 | 发表时间(年) | 试验组治疗方案 | 对照组治疗方案 | 样本量(试验组/对照组,例) | 治愈率〔例(%)〕 | 有效率〔例(%)〕 | 治疗后VAS( | 改良Jadad量表评分(分) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 试验组 | 对照组 | 试验组 | 对照组 | 试验组 | 对照组 | ||||||
| 陈硕康[ | 2017 | 通元针法每周3次,共12周 | 氟桂利嗪(10 mg)每晚1次,共12周 | 38/36 | 47.37(18/38) | 38.89(14/36) | 97.37(37/38) | 94.44(34/36) | 4.55±0.69 | 5.09±0.97 | 7 |
| 关淑婷[ | 2019 | 治神六穴每周5次,共4周 | 氟桂利嗪(5 mg)每晚1次,每周5次,共4周 | 60/59 | 5.00(3/60) | 1.69(1/59) | 96.67(58/60) | 81.36(48/59) | 2.62±0.89 | 3.39±0.78 | 5 |
| 戴睛[ | 2017 | 骨边刺每周3次,共4周 | 尼莫地平(40 mg)每日3次,共4周 | 35/45 | 17.14(6/35) | 8.89(4/45) | 94.29(33/35) | 75.56(34/45) | 3.14±2.00 | 4.42±2.27 | 1 |
| 郭伟[ | 2011 | 常规针刺每日1次,共20 d | 阿司匹林(0.3 g)每日3次,共20 d | 35/33 | 80.00(28/35) | 0(0/33) | 94.29(33/35) | 42.42(14/33) | 0.30±0.83 | 2.74±1.68 | 2 |
| 刘云霞[ | 2020 | 常规针刺每日1次,共21 d | 氟桂利嗪(5 mg)每日2次,共30 d | 59/59 | 59.32(35/59) | 32.20(19/59) | 96.61(57/59) | 83.05(49/59) | 3.10±1.58 | 4.60±1.87 | 1 |
| 舒伟[ | 2017 | 常规针刺每日1次,共4周 | 氟桂利嗪(10 mg)每晚1次,共4周 | 58/57 | 41.38(24/58) | 28.07(16/57) | 98.28(57/58) | 89.47(51/57) | 3.41±1.26 | 3.38±1.02 | 2 |
| 苏慧媛[ | 2016 | 常规针刺每日1次,共4周 | 氟桂利嗪(5 mg)每晚1次,共4周 | 35/32 | 28.57(10/35) | 9.38(3/32) | 91.43(32/35) | 78.13(25/32) | 1.54±0.74 | 2.86±0.92 | 2 |
| 崔晶[ | 2016 | 常规针刺每周2次,共6周 | 对乙酰氨基酚(1 g)按需服用,共6周 | 32/33 | 25.00(8/32) | 6.06(2/33) | 87.50(28/32) | 69.70(23/33) | 2.73±2.22 | 3.11±1.72 | 7 |
| 张瑞秋[ | 2021 | 常规针刺每日1次,共24 d | 氟桂利嗪(5 mg)每晚1次,共24 d | 43/42 | 18.60(8/43) | 4.76(2/42) | 90.70(39/43) | 73.81(31/42) | 3.42±1.14 | 5.48±1.40 | 3 |
| 陈慧[ | 2019 | 胆经每日1次,共20 d | 氟桂利嗪(5 mg)每晚1次,共20 d | 50/48 | 64.00(32/50) | 22.92(11/48) | 90.00(45/50) | 72.92(35/48) | 0.85±0.28 | 1.13±1.09 | 3 |
| 于明[ | 2017 | 胆经、三焦经每周3次,共12周 | 氟桂利嗪(5 mg)每晚1次,每周5 d,共12周 | 41/43 | 48.78(20/41) | 41.86(18/43) | 95.12(39/41) | 88.37(38/43) | 2.07±0.31 | 2.40±0.47 | 1 |
| 卢金荣[ | 2014 | 头部腧穴每日1次,共10 d | 尼莫地平(40 mg)每日3次,共10 d | 48/48 | 41.67(20/48) | 10.42(5/48) | 91.67(44/48) | 62.50(30/48) | 2.17±1.88 | 3.76±2.42 | 1 |
| 杨佳[ | 2018 | 头部腧穴每周3次,共4周 | 氟桂利嗪(用法用量不详) | 20/19 | 75.00(15/20) | 52.63(10/19) | 95.00(19/20) | 78.95(15/19) | 3.40±1.39 | 4.58±1.17 | 6 |
| 景允南[ | 2021 | 透刺法隔日1次,共28 d | 氟桂利嗪(5 mg)每晚1次,共4周 | 31/33 | 58.06(18/31) | 33.33(11/33) | 96.77(30/31) | 87.88(29/33) | 2.71±1.55 | 3.94±1.46 | 7 |
| 刘波[ | 2021 | 透刺法每日1次,共28 d | 氟桂利嗪(5 mg)每晚1次,共4周 | 40/40 | 15.00(6/40) | 5.00(2/40) | 97.50(39/40) | 85.00(34/40) | 2.57±1.05 | 3.54±1.19 | 1 |
| 杨雄庆[ | 2013 | 透刺法隔日1次,共40 d | 氟桂利嗪(5 mg)每日1次,共30 d | 30/28 | 56.67(17/30) | 28.57(8/28) | 96.67(29/30) | 78.57(22/28) | 2.40±1.04 | 4.12±1.10 | 2 |
| 杨旭光[ | 2006 | 四关穴每周3次,共4周 | 氟桂利嗪(5 mg)每日2次,共4周 | 35/33 | 22.86(8/35) | 15.15(5/33) | 91.43(32/35) | 72.73(24/33) | 1.31±0.57 | 1.67±0.85 | 5 |
| 治疗方案 | 治愈率 | 有效率 | VAS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RR(95%CI) | I2(%) | P值 | 效应模型 | RR(95%CI) | I2(%) | P值 | 效应模型 | MD(95%CI) | I2(%) | P值 | 效应模型 | |
| 常规针刺[ | 2.62(1.93,3.55) | 45.2 | 0.104 | 固定 | 1.19(1.09,1.30) | 57.6 | 0.038 | 随机 | -1.29(-2.05,-0.52) | 91.9 | <0.001 | 随机 |
| 胆经腧穴[ | 1.78(0.76,4.19) | 81.8 | 0.019 | 随机 | 1.15(1.03,1.30) | 23.8 | 0.252 | 固定 | -0.32(-0.48,-0.16) | 0 | 0.845 | 固定 |
| 头部腧穴[ | 2.23(0.82,6.06) | 74.4 | 0.048 | 随机 | 1.38(1.15,1.65) | 20.7 | 0.262 | 固定 | -1.37(-1.96,-0.78) | 0 | 0.497 | 固定 |
| 透刺法[ | 1.96(1.28,2.98) | 0 | 0.801 | 固定 | 1.15(1.05,1.27) | 0 | 0.683 | 固定 | -1.29(-1.62,-0.96) | 49.8 | 0.136 | 固定 |
Table 2 Meta-analysis and heterogeneity test of cure rate,efficiency rate and VAS for each treatment plan
| 治疗方案 | 治愈率 | 有效率 | VAS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RR(95%CI) | I2(%) | P值 | 效应模型 | RR(95%CI) | I2(%) | P值 | 效应模型 | MD(95%CI) | I2(%) | P值 | 效应模型 | |
| 常规针刺[ | 2.62(1.93,3.55) | 45.2 | 0.104 | 固定 | 1.19(1.09,1.30) | 57.6 | 0.038 | 随机 | -1.29(-2.05,-0.52) | 91.9 | <0.001 | 随机 |
| 胆经腧穴[ | 1.78(0.76,4.19) | 81.8 | 0.019 | 随机 | 1.15(1.03,1.30) | 23.8 | 0.252 | 固定 | -0.32(-0.48,-0.16) | 0 | 0.845 | 固定 |
| 头部腧穴[ | 2.23(0.82,6.06) | 74.4 | 0.048 | 随机 | 1.38(1.15,1.65) | 20.7 | 0.262 | 固定 | -1.37(-1.96,-0.78) | 0 | 0.497 | 固定 |
| 透刺法[ | 1.96(1.28,2.98) | 0 | 0.801 | 固定 | 1.15(1.05,1.27) | 0 | 0.683 | 固定 | -1.29(-1.62,-0.96) | 49.8 | 0.136 | 固定 |
| 治疗方案 | 治疗次数(加权平均值) | 治愈率的RR | 有效率的RR | VAS的MD | 改良Jadad评分(加权平均值) |
|---|---|---|---|---|---|
| 通元针法[ | 36.00 | 1.22 | 1.03 | -0.54 | 7.00 |
| 治神六穴[ | 20.00 | 2.95 | 1.19 | -0.77 | 5.00 |
| 骨边刺[ | 12.00 | 1.93 | 1.25 | -1.28 | 1.00 |
| 常规针刺[ | 22.69 | 2.62 | 1.19 | -1.29 | 2.56 |
| 胆经腧穴[ | 27.38 | 1.78 | 1.15 | -0.32 | 2.08 |
| 头部腧穴[ | 10.58 | 2.23 | 1.38 | -1.37 | 2.44 |
| 透刺法[ | 21.26 | 1.96 | 1.15 | -1.29 | 3.19 |
| 四关穴[ | 12.00 | 1.51 | 1.37 | -0.36 | 5.00 |
Table 3 Characteristics of each criterion for different treatment plans
| 治疗方案 | 治疗次数(加权平均值) | 治愈率的RR | 有效率的RR | VAS的MD | 改良Jadad评分(加权平均值) |
|---|---|---|---|---|---|
| 通元针法[ | 36.00 | 1.22 | 1.03 | -0.54 | 7.00 |
| 治神六穴[ | 20.00 | 2.95 | 1.19 | -0.77 | 5.00 |
| 骨边刺[ | 12.00 | 1.93 | 1.25 | -1.28 | 1.00 |
| 常规针刺[ | 22.69 | 2.62 | 1.19 | -1.29 | 2.56 |
| 胆经腧穴[ | 27.38 | 1.78 | 1.15 | -0.32 | 2.08 |
| 头部腧穴[ | 10.58 | 2.23 | 1.38 | -1.37 | 2.44 |
| 透刺法[ | 21.26 | 1.96 | 1.15 | -1.29 | 3.19 |
| 四关穴[ | 12.00 | 1.51 | 1.37 | -0.36 | 5.00 |
| 评价指标 | 信息熵值(e) | 差异度(d) | 权重系数(w) |
|---|---|---|---|
| 治疗次数 | 0.961 6 | 0.038 4 | 21.27% |
| 治愈率 | 0.983 6 | 0.016 4 | 9.08% |
| 有效率 | 0.998 0 | 0.002 0 | 1.09% |
| VAS | 0.941 5 | 0.058 5 | 32.42% |
| 改良Jadad评分 | 0.934 7 | 0.065 3 | 36.15% |
Table 4 The entropy value,variance and weight coefficient of each criterion
| 评价指标 | 信息熵值(e) | 差异度(d) | 权重系数(w) |
|---|---|---|---|
| 治疗次数 | 0.961 6 | 0.038 4 | 21.27% |
| 治愈率 | 0.983 6 | 0.016 4 | 9.08% |
| 有效率 | 0.998 0 | 0.002 0 | 1.09% |
| VAS | 0.941 5 | 0.058 5 | 32.42% |
| 改良Jadad评分 | 0.934 7 | 0.065 3 | 36.15% |
| 评价指标 | 正理想解(A+) | 负理想解(A-) |
|---|---|---|
| 治疗次数 | 0.213 | 0.062 |
| 治愈率 | 0.091 | 0.038 |
| 有效率 | 0.011 | 0.008 |
| VAS | 0.324 | 0.076 |
| 改良Jadad评分 | 0.362 | 0.052 |
Table 5 Positive and negative ideal solutions for each criterion
| 评价指标 | 正理想解(A+) | 负理想解(A-) |
|---|---|---|
| 治疗次数 | 0.213 | 0.062 |
| 治愈率 | 0.091 | 0.038 |
| 有效率 | 0.011 | 0.008 |
| VAS | 0.324 | 0.076 |
| 改良Jadad评分 | 0.362 | 0.052 |
| 方案 | 正理想解距离(D+) | 负理想解距离(D-) | 相对贴近度(C) | 排序结果 |
|---|---|---|---|---|
| 通元针法 | 0.253 | 0.314 | 0.554 | 2 |
| 治神六穴 | 0.202 | 0.244 | 0.547 | 3 |
| 骨边刺 | 0.313 | 0.260 | 0.454 | 7 |
| 常规针刺 | 0.257 | 0.250 | 0.493 | 5 |
| 胆经腧穴 | 0.380 | 0.062 | 0.139 | 8 |
| 头部腧穴 | 0.237 | 0.301 | 0.560 | 1 |
| 透刺法 | 0.227 | 0.260 | 0.534 | 4 |
| 四关穴 | 0.265 | 0.242 | 0.477 | 6 |
Table 6 Final evaluation results of each treatment plan based on TOPSIS method
| 方案 | 正理想解距离(D+) | 负理想解距离(D-) | 相对贴近度(C) | 排序结果 |
|---|---|---|---|---|
| 通元针法 | 0.253 | 0.314 | 0.554 | 2 |
| 治神六穴 | 0.202 | 0.244 | 0.547 | 3 |
| 骨边刺 | 0.313 | 0.260 | 0.454 | 7 |
| 常规针刺 | 0.257 | 0.250 | 0.493 | 5 |
| 胆经腧穴 | 0.380 | 0.062 | 0.139 | 8 |
| 头部腧穴 | 0.237 | 0.301 | 0.560 | 1 |
| 透刺法 | 0.227 | 0.260 | 0.534 | 4 |
| 四关穴 | 0.265 | 0.242 | 0.477 | 6 |
| [1] |
GBD Neurology Collaborators. Global,regional,and national burden of neurological disorders,1990-2016:a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet Neurol,2019,18(5):459-480. DOI:10.1016/S1474-4422(18)30499-X.
|
| [2] |
Headache Classification Committee of the International Headache Society(IHS)the international classification of headache disorders,3rd edition[J]. Cephalalgia,2018,38(1):1-211. DOI:10.1177/0333102417738202.
|
| [3] |
|
| [4] |
|
| [5] |
American headache society. The American Headache Society position statement on integrating new migraine treatments into clinical practice[J]. Headache,2019,59(1):1-18. DOI:10.1111/head.13456.
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
娄红岩. 针灸治疗偏头痛的网状Meta分析[D]. 乌鲁木齐:新疆医科大学,2020.
|
| [12] |
王文通,王恩忠,李胜,等. 基于数据挖掘技术分析单纯针刺治疗偏头痛的取穴规律[J]. 中国中西医结合影像学杂志,2021,19(4):307-310. DOI:10.3969/j.issn.1672-0512.2021.04.001.
|
| [13] | |
| [14] |
|
| [15] |
刘永军,马林超,刘国恩. 多指标决策分析在卫生技术评价中的应用研究[J]. 中国药物经济学,2014,9(6):9-12.
|
| [16] |
王健,孟庆跃,
|
| [17] |
|
| [18] |
王利然,宁文华,杨丽红,等. 针灸治疗中风后肩手综合征的优势方案筛选研究[J]. 针灸临床杂志,2022,38(2):46-52. DOI:10.19917/j.cnki.1005-0779.022032.
|
| [19] |
秦懿囡,王利然,谢玥,等. 近10年针灸治疗血管性痴呆的优势方案筛选研究[J]. 中华中医药杂志,2020,35(8):4109-4112.
|
| [20] |
张晶晶,黎波,杜元灏,等. 针灸治疗慢性疲劳综合征的优势方案筛选研究[J]. 中国中医基础医学杂志,2020,26(8):1123-1126,1217. DOI:10.3969/j.issn.1006-3250.2020.08.027.
|
| [21] |
刘佳琳,杜元灏,胡亚才,等. 基于层次分析法的针灸治疗脑卒中后抑郁症的优势方案研究[J]. 辽宁中医杂志,2018,45(3):595-598. DOI:10.13192/j.issn.1000-1719.2018.03.044.
|
| [22] |
张晶晶,杜元灏,李晶,等. 针灸治疗股外侧皮神经炎的优势方案筛选研究[J]. 中国针灸,2019,39(3):323-328. DOI:10.13703/j.0255-2930.2019.03.026.
|
| [23] |
|
| [24] | |
| [25] |
张瑞秋,陈英华. "标本、根结"理论指导针刺治疗偏头痛的临床观察[J]. 广州中医药大学学报,2021,38(2):306-310. DOI:10.13359/j.cnki.gzxbtcm.2021.02.016.
|
| [26] |
于明,周倩文,徐宇浩. 针刺对慢性偏头痛患者血浆CGRP、β-EP和5-HT的影响[J]. 江苏医药,2017,43(10):710-713. DOI:10.19460/j.cnki.0253-3685.2017.10.011.
|
| [27] |
杨旭光. 电针"四关"穴治疗无先兆偏头痛的近期疗效和远期疗效的临床观察[D]. 成都:成都中医药大学,2006.
|
| [28] | |
| [29] |
杨佳,沈燕,王舒. 针刺与盐酸氟桂利嗪对比治疗偏头痛的预防性临床疗效观察[J]. 世界科学技术-中医药现代化,2018,20(5):750-755. DOI:10.11842/wst.2018.05.021.
|
| [30] |
苏慧媛,李晶,杜元灏. 调神疏肝针刺法治疗偏头痛35例疗效观察[J]. 湖南中医杂志,2016,32(8):102-103. DOI:10.16808/j.cnki.issn1003-7705.2016.08.046.
|
| [31] |
舒伟,彭天忠,黄学娣,等. 间歇式柔肝调神针刺法预防性治疗偏头痛疗效观察[J]. 上海针灸杂志,2017,36(6):727-730. DOI:10.13460/j.issn.1005-0957.2017.06.0727.
|
| [32] |
卢金荣,姚素媛. 电针治疗偏头痛48例疗效观察[J]. 中国中医药科技,2014,21(1):92.
|
| [33] | |
| [34] | |
| [35] |
景允南. 疏肝宁神针刺法预防性治疗偏头痛的临床疗效观察[D]. 哈尔滨:黑龙江中医药大学,2021.
|
| [36] | |
| [37] |
关淑婷,冶尕西,张瑜,等. 针刺"治神六穴"治疗偏头痛的临床疗效评价[J]. 时珍国医国药,2019,30(7):1664-1666. DOI:10.3969/j.issn.1008-0805.2019.07.042.
|
| [38] |
戴晴,江彬,杨柳,等. 骨边刺法治疗偏头痛35例疗效观察[J]. 浙江中医杂志,2017,52(9):687-688. DOI:10.3969/j.issn.0411-8421.2017.09.041.
|
| [39] |
崔晶. 针刺治疗瑞士白种人无先兆型偏头痛的临床疗效观察[D]. 成都:成都中医药大学,2016.
|
| [40] |
陈硕康. 赖氏通元针法治疗肝阳上亢型无先兆型偏头痛的临床观察[D]. 广州:广州中医药大学,2017.
|
| [41] | |
| [42] |
周怡,赵小龙. 医学信息分析与决策[M]. 北京:电子工业出版社,2014.
|
| [43] |
杨丰文,张俊华,张伯礼. 中医药网状Meta分析质量评价[J]. 中华中医药杂志,2018,33(10):4599-4606.
|
| [44] |
刘佳琳,杜元灏,黎波,等. 基于多指标决策法的针灸治疗枕神经痛的优势方案研究[J]. 辽宁中医杂志,2019,46(9):1799-1803. DOI:10.13192/j.issn.1000-1719.2019.09.002.
|
| [45] |
闫超. 应用多指标决策方法评价选择针灸治疗痤疮优势方案[J]. 湖南中医杂志,2017,33(11):136-138. DOI:10.16808/j.cnki.issn1003-7705.2017.11.068
|
| [46] |
|
| [47] |
|
| [1] | LI Yutong, ZHAO Danting, JIANG Feng, WANG Yanna, LIU Yizong, LIANG Wenjuan, LU Jiahai. Systematic Review and Meta-analysis of the Efficacy and Safety of mRNA and Recombinant Protein Subunit Vaccines Against Respiratory Syncytial Virus [J]. Chinese General Practice, 2026, 29(19): 2744-2752. |
| [2] | ZHANG Wenbo, WANG Junlong, ZHANG Yuping, JIANG Shuai, WANG Huaqi. The Risk of Pre-COPD Populations Progressing to COPD under Different Criteria: a Meta-analysis [J]. Chinese General Practice, 2026, 29(19): 2735-2743. |
| [3] | TIAN Anni, YANG Jing, SUN Jing, WANG Shichun. Effect of Robot-assisted Training on the Recovery of Hand Motor Function in Patients with Different Stages of Stroke: a Meta-analysis [J]. Chinese General Practice, 2026, 29(14): 1911-1920. |
| [4] | ZHAN Li, HENG Zhaoyang, HE Liangyu, ZHAO Jie, CHEN Jie, XING Jinshan. Efficacy and Safety of CAR-T Therapy Targeting the B Cell Maturation Antigen on Relapsed/Refractory Multiple Myeloma in Chinese People: a Meta-analysis [J]. Chinese General Practice, 2026, 29(14): 1921-1930. |
| [5] | LI Li, XU Tianchao, DONG Xiaomei, HUANG Hongfei, CUI Gang, LI Dongdong, ZHANG Ou, FAN Lin, WANG Qi. The Effect of Kidney Tonifying and Brain Strengthening Acupuncture Combined with Sertraline in the Treatment of Elderly Depression: a Randomized Controlled Trial [J]. Chinese General Practice, 2026, 29(11): 1399-1404. |
| [6] | Dongfang Hospital, Beijing University of Chinese Medicine, Chinese Sleep Research Society Special Committee on Traditional Chinese Medicine Sleep Medicine. Technical Specification for Electroacupuncture Therapy in Treating Chronic Insomnia [J]. Chinese General Practice, 2026, 29(11): 1367-1373. |
| [7] | WANG Fei, HAN Weiyu, SUN Tao. Moxibustion Combined with Three-step Therapy in the Treatment of Cancer Pain: a Network Meta-analysis [J]. Chinese General Practice, 2026, 29(09): 1203-1211. |
| [8] | PEI Zhiyi, ZHANG Xiaoxin, LIN Jiayi, ZHANG Xiangyi, KANG Xiaofeng. Systematic Review of the Quality and Application of Patient Decision Aids in Cardiovascular Disease Based on IPDAS 4.0 Criteria [J]. Chinese General Practice, 2026, 29(07): 945-952. |
| [9] | ZHANG Ling, HUANG Shuangying, XU Hui, MEI Huiting, HONG Yongping. Effects of Different Exercise Types on Fall Efficacy in the Elderly: a Network Meta-analysis [J]. Chinese General Practice, 2026, 29(06): 741-751. |
| [10] | ZHAO Xuejiao, LI Juan, LI Yujie, LU Ting, Xian Lihong, YAN Huan. Prevalence Trends and Influencing Factors for Post-stroke Cognitive Impairment in China: a Meta-analysis [J]. Chinese General Practice, 2026, 29(03): 380-392. |
| [11] | ZHOU Wenchao, LIANG Jiaqi, YAO Shangman, XUE Zhao, LIU Long, GUO Xiangjie. Identification of Shared Loci between Hypertension and Parkinson's Disease [J]. Chinese General Practice, 2026, 29(02): 201-206. |
| [12] | XIANG Fengling, WANG Yuankun, WANG Xiaoyan, HE Shengjie, GAN Jinhua. The Prevalence of Hyperuricemia among Children and Adolescents in China: a Meta-analysis [J]. Chinese General Practice, 2025, 28(33): 4206-4213. |
| [13] | SHANG Luxiang, ZHU Mingqi, ZHOU Xianhui, GAO Mei, TANG Baopeng, HOU Yinglong. Prevalence and Risk Factors of Atrial Fibrillation among Adults in China: a Meta-analysis [J]. Chinese General Practice, 2025, 28(33): 4192-4198. |
| [14] | GU Jianhui, JING Yuzhen, LU Junfeng, YANG Lina, WEI Qinglin, JIA Yongnan. Clinical Study of Acupuncture Combined with Vitamin D on Behavioral and Gastrointestinal Symptoms in Children with Autism Spectrum Disorder [J]. Chinese General Practice, 2025, 28(33): 4180-4186. |
| [15] | XU Jialan, YAN Hong, WEN Jun, ZHOU Zitong, WANG Siyu. Prevalence of Potentially Inappropriate Medication in Older Adults with Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(30): 3815-3822. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||